Quick Answer
AbCellera Biologics Inc. reported Stockholders Equity of $966.90 million for fiscal year 2025.
AbCellera Biologics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $966.90M | -8.4% |
| 2024 | $1.06B | -8.4% |
| 2023 | $1.15B | -6.6% |
| 2022 | $1.23B | +20.2% |
| 2021 | $1.03B | +23.5% |
| 2020 | $830.51M | +8000.9% |
| 2019 | $10.25M | -11.7% |
| 2018 | $11.61M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $964.04M | -10.6% | -4.3% |
| June 30, 2025 | $1.01B | -9.4% | -1.6% |
| March 31, 2025 | $1.02B | -9.5% | -3.1% |
| December 31, 2024 | $1.06B | -8.4% | -2.0% |
| September 30, 2024 | $1.08B | -8.9% | -3.0% |
| June 30, 2024 | $1.11B | -7.0% | -1.7% |
| March 31, 2024 | $1.13B | -6.5% | -1.9% |
| December 31, 2023 | $1.15B | -6.6% | -2.6% |
- AbCellera Biologics Inc. showed a decrease of -8.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, AbCellera Biologics Inc.’s stockholders equity has grown by 8228.9% (from $11.61 million to $966.90 million).
- The most recent figure is from AbCellera Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: